Madsen, L.W.; Christensen, P.B.; Hansen, J.F.; Røge, B.T.; Holm, D.K.; Dröse, S.; Øvrehus, A.
Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin—A Randomized Controlled Clinical Trial. Viruses 2022, 14, 614.
https://doi.org/10.3390/v14030614
AMA Style
Madsen LW, Christensen PB, Hansen JF, Røge BT, Holm DK, Dröse S, Øvrehus A.
Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin—A Randomized Controlled Clinical Trial. Viruses. 2022; 14(3):614.
https://doi.org/10.3390/v14030614
Chicago/Turabian Style
Madsen, Lone W., Peer B. Christensen, Janne F. Hansen, Birgit T. Røge, Dorte K. Holm, Sandra Dröse, and Anne Øvrehus.
2022. "Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin—A Randomized Controlled Clinical Trial" Viruses 14, no. 3: 614.
https://doi.org/10.3390/v14030614
APA Style
Madsen, L. W., Christensen, P. B., Hansen, J. F., Røge, B. T., Holm, D. K., Dröse, S., & Øvrehus, A.
(2022). Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin—A Randomized Controlled Clinical Trial. Viruses, 14(3), 614.
https://doi.org/10.3390/v14030614